1. US FDA. Food and drug administration work plan and proposed funding allocations of FDA innovation account—required by section 1002 of the 21st Century Cures Act 6 (Public Law 114-225). 2017. https://www.fda.gov/files/Proposed-FDA-Work-Plan-for-21st-Century-Cures-Act-Innovation-Account-Activities-as-Submitted-to-Science-Board.pdf. Accessed 25 Sept 2021.
2. US FDA. Best practices for conducting and reporting pharmacoepidemiologic safety studies using electronic healthcare data. 2013. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/best-practices-conducting-and-reporting-pharmacoepidemiologic-safety-studies-using-electronic. Accessed 25 Sept 2021.
3. European Medicines Agency. Guideline on good pharmacovigilance practices(GVP): Module VIII-Post-authorisation safety studies (Rev 3). 2017. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-viii-post-authorisation-safety-studies-rev-3_en.pdf. Accessed 25 Sept 2021.
4. Pharmaceuticals and Medical Devices Agency. Guidelines for conducting drug epidemiology research in evaluating drug safety using medical information databases [in Japanese]. 2014. https://www.pmda.go.jp/safety/surveillance-analysis/0032.html. Accessed 25 Sept 2021.
5. European Medicines Agency. Scientific Guidance on Post-authorisation Efficacy Studies. 2016. https://www.ema.europa.eu/en/documents/scientific-guideline/scientific-guidance-post-authorisation-efficacy-studies-first-version_en.pdf. Accessed 26 Sept 2021.